CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 9 of 9

Some of the metrics are blocked by your
consent settings
Systolic Blood Pressure Trajectory and Outcomes in Acute Intracerebral Hemorrhage
(Ovid Technologies (Wolters Kluwer Health), 2026-04-14)
Xia Wang
;
Thanh G. Phan
;
Xinwen Ren
;
Henry H. Ma
;
Qiang Li
1
Some of the metrics are blocked by your
consent settings
Mediation Analysis to Identify Individual Component Effects of the Care Bundle to Improve Functional Outcome After ICH in the INTERACT3 Study
(Ovid Technologies (Wolters Kluwer Health), 2025-10)
Xinwen Ren
;
Qiang Li
;
Menglu Ouyang
;
Laurent Billot
;
Xiaoying Chen
1Scopus© Citations 6
Some of the metrics are blocked by your
consent settings
Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial
(Elsevier BV, 2025-05)
Craig S Anderson
;
Debbie Summers
;
Menglu Ouyang
;
Yi Sui
;
Brenda Johnson
2Scopus© Citations 15
Some of the metrics are blocked by your
consent settings
Impact of guideline‐directed medical therapy on systolic blood pressure and cardiovascular outcomes in patients with heart failure and low blood pressure: A systematic review and meta‐analysis
(2024)
Jingwei Li
;
Yunlong Chen
;
Yi Wang
;
Xiaoyan Liu
;
Ping Li
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>Existing research indicates that patients with heart failure (HF) may have restricted access to guideline‐directed medical therapy (GDMT) when their blood pressure (BP) is comparatively low. However, recent clinical trials suggest that HF patients with low BP could still benefit from certain HF medications, which have a minimal impact on BP. This systematic review and meta‐analysis was conducted to determine whether this applies to all GDMT.</jats:p></jats:sec><jats:sec><jats:title>Methods and results</jats:title><jats:p>A systematic search of MEDLINE and EMBASE was conducted for studies published from inception to 10 January 2024. Randomized controlled trials were selected if they reported on the longitudinal change of systolic BP (SBP) due to GDMT, or the risks of cardiovascular events in HF patients based on SBP categories. Weighted mean difference (WMD), hazard ratio or relative risk, and corresponding 95% confidence intervals (CI) were pooled for meta‐analysis where possible. Data from 20 studies, encompassing information on 84 782 individuals, were analysed. Overall, GDMT is associated with lower SBP (WMD, −2.16; 95% CI −2.86 to −1.46), with no significant difference between baseline low and non‐low BP subgroups (interaction <jats:italic>p</jats:italic> = 0.810). However, SBP of the treatment group increased by 5.8 mmHg from baseline in the low SBP subgroup during follow‐up, while it decreased by 4.0 mmHg in the baseline non‐low SBP subgroup. GDMT demonstrated similar cardiovascular benefits and risk of hypotension between low and non‐low SBP subgroups (interaction <jats:italic>p</jats:italic> = 0.318 and 0.903, respectively).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Guideline‐directed medical therapy is associated with a negligible decrease in SBP, but can provide similar cardiovascular benefits in both low and non‐low SBP HF patients, with no significant interaction with SBP as to hypotension. Therefore, GDMT should be initiated and maintained in HF patients with low BP.</jats:p></jats:sec>
2Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
ASSOCIATIONS OF EARLY SYSTOLIC BLOOD PRESSURE CONTROL AND BRAIN OEDEMA AFTER THROMBOLYSIS-ELIGIBLE ACUTE ISCHEMIC STROKE: SECONDARY ANALYSIS OF THE ENCHANTED STUDY
(2023)
Liu, F.
;
Chen, C.
;
Ren, X
;
Zhang, G.
;
Zhang, L
2
Some of the metrics are blocked by your
consent settings
Statistical analysis plan for the second INTEnsive blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT2): a large-scale investigation to solve longstanding controversy over the most appropriate management of elevated blood pressure in the hyperacute phase of intracerebral hemorrhage
(2013)
Craig Anderson
;
Emma Heeley
;
Stephane Heritier
;
Hisatomi Arima
;
Mark Woodward
The Statistical analysis plan (SAP) for the second INTEnsive blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT2).
2Scopus© Citations 10
Some of the metrics are blocked by your
consent settings
Priorities to reduce the burden of stroke in Latin American countries
(2019)
Sheila C Ouriques Martins
;
Claudio Sacks
;
Werner Hacke
;
Michael Brainin
;
Francisco de Assis Figueiredo
Scopus© Citations 107 7
Some of the metrics are blocked by your
consent settings
Self-reported Snoring Patterns Predict Stroke Events in High-Risk Patients With OSA
(2020)
Jingwei Li
;
R. Doug McEvoy
;
Danni Zheng
;
Kelly A. Loffler
;
Xia Wang
Scopus© Citations 25 2
Some of the metrics are blocked by your
consent settings
Sleep duration and risk of cardiovascular events: The SAVE study
(2020)
Jingwei Li
;
Danni Zheng
;
Kelly A Loffler
;
Xia Wang
;
R Doug McEvoy
<jats:sec><jats:title>Background and aim</jats:title><jats:p> Controversy exists regarding cardiovascular risk in relation to sleep duration. We determined sleep duration and major recurrent cardiovascular event associations in patients with obstructive sleep apnoea and established cardiovascular disease. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> Secondary analyses of the international, multicenter, Sleep Apnea Cardiovascular Endpoints trial. Sleep duration was estimated from overnight home oximetry (ApneaLink monitor) used for obstructive sleep apnoea diagnosis. Cox proportional hazards models were used to determine associations of categorized sleep duration (<6 h, 6–8 h (reference), and >8 h) and major cardiovascular outcomes: primary composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and any hospitalization for unstable angina, heart failure, or transient ischemic attack; secondary composite of cardiac and cerebral (stroke/transient ischemic attack) events. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Oximetry-derived sleep duration estimates were available in 2687 participants (mean 61.2 years, 80.9% males) who experienced a total of 436 cardiovascular events over a mean follow-up of 3.7 years. Compared to the reference category, sleep duration was not associated with risk of the primary composite cardiovascular outcome (adjusted hazard ratio (HR) 1.00, 95% confidence interval 0.76–1.33, and HR 1.22, 95% confidence interval 0.98–1.52, for sleep duration <6 and >8 h, respectively). However, long sleep was associated with increased cerebral events (HR 1.67, 95% confidence interval 1.17–2.39; P = 0.005) and stroke alone (HR 1.79, 95% confidence interval 1.22–2.63; P = 0.003). </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Long sleep duration is associated with an increased risk of stroke but not cardiac events in obstructive sleep apnoea patients with existing cardiovascular disease. </jats:p></jats:sec><jats:sec><jats:title>Clinical trial registration</jats:title><jats:p> The trial is registered at ClinicalTrials.gov (NCT00738179). </jats:p></jats:sec>
8Scopus© Citations 27

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results